Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data
Credit: Team BIPID, Université Paris Cité (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)
Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data
#####
In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002249
Article Title: Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection
Author Countries: France, Spain, United Kingdom, United States, Papua New Ginea
Funding: BTN received funding from IAME UMR 137, Université Paris Cité, INSERM, F-75018, Paris, France (https://www.iame-research.center/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Journal
PLoS Biology
DOI
10.1371/journal.pbio.3002249
Method of Research
Computational simulation/modeling
Subject of Research
Not applicable
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: DWG, DEH, and ATR work for SIGA Technologies Inc. Other authors declare no conflicts of interests.
